Sight Sciences (NASDAQ:SGHT) Releases Earnings Results

Key Points

• Revenue reached a record $24.9 million, up 25% year over year, beating analyst estimates of $23.55 million; adjusted EPS of ($0.12) matched consensus.
• Management raised 2026 revenue guidance to $92 million–$93 million, with higher outlooks for both IDE and IG businesses. IDE revenue rose 45% sequentially to a record $3.9 million, while IG revenue grew 7% to $21 million.
• Quarterly cash use declined to $2.4 million from $9.1 million a year earlier, and the company ended the quarter with $77.4 million in cash. Sight Sciences said it remains focused on cash-flow breakeven and extended its debt interest-only period through August 2027.

Sight Sciences (NASDAQ:SGHT - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.12) EPS for the quarter, meeting the consensus estimate of ($0.12), FiscalAI reports. The business had revenue of $24.92 million during the quarter, compared to analyst estimates of $23.55 million. Sight Sciences had a negative net margin of 35.69% and a negative return on equity of 43.39%.

Here are the key takeaways from Sight Sciences' conference call:

• Sight Sciences reported record third-quarter revenue of $24.9 million, up 25% year over year, and raised 2026 revenue guidance to $92 million–$93 million, implying about 20% growth. Adjusted operating expense guidance was maintained at $92 million–$94 million.
• IDE revenue reached a record $3.9 million, up 45% sequentially, prompting the company to raise its full-year IDE outlook to approximately $12 million. Ordering accounts and utilization both increased, though TearCare growth remains concentrated in a limited reimbursed footprint and broader payer access is not yet assured.
• IG revenue grew 7% to $21 million, with active accounts at a record high; full-year IG guidance was raised to $80 million–$81 million. The company launched its next-generation OMNI Ultra in the U.S. and said expanded Aetna coverage adds about 25 million covered lives.
• Cash used in the quarter fell to $2.4 million from $9.1 million a year earlier, while year-to-date cash use improved 48%; the company ended the quarter with $77.4 million in cash. Management said it remains focused on cash-flow breakeven and extended the debt interest-only period through August 2027.

Sight Sciences Price Performance

NASDAQ:SGHT traded up $0.26 during midday trading on Wednesday, hitting $9.68. 629,733 shares of the stock were exchanged, compared to its average volume of 274,743. The company has a market capitalization of $533.27 million, a price-to-earnings ratio of -17.29 and a beta of 2.44. The company has a current ratio of 4.95, a quick ratio of 4.67 and a debt-to-equity ratio of 0.58. Sight Sciences has a one year low of $3.38 and a one year high of $10.06. The business has a 50-day moving average price of $8.63 and a two-hundred day moving average price of $6.03.

Wall Street Analyst Weigh In

A number of research firms have issued reports on SGHT. Weiss Ratings reissued a "sell (e+)" rating on shares of Sight Sciences in a research note on Friday, August 7th. HC Wainwright began coverage on shares of Sight Sciences in a research note on Thursday, October 15th. They issued a "buy" rating and a $14.00 price target on the stock. UBS Group lifted their price target on Sight Sciences from $7.00 to $8.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Citigroup boosted their price objective on Sight Sciences from $8.00 to $10.00 and gave the stock a "neutral" rating in a research report on Monday, October 5th. Finally, Wall Street Zen raised Sight Sciences from a "hold" rating to a "buy" rating in a report on Saturday, August 8th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Sight Sciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $9.25.

Insider Transactions at Sight Sciences

In other news, CTO David Badawi sold 7,797 shares of the company's stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $9.05, for a total value of $70,562.85. Following the completion of the sale, the chief technology officer owned 1,975,075 shares in the company, valued at $17,874,428.75. This represents a 0.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO James Rodberg sold 7,208 shares of the firm's stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $8.85, for a total value of $63,790.80. Following the transaction, the chief financial officer directly owned 216,829 shares of the company's stock, valued at $1,918,936.65. This represents a 3.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 47,646 shares of company stock valued at $429,157. Company insiders own 30.40% of the company's stock.

Sight Sciences Company Profile

Sight Sciences, Inc is an ophthalmic medical technology company focused on developing and commercializing products designed to address the underlying causes of certain eye diseases. The company's portfolio is centered on minimally invasive and non-invasive procedures intended to improve patient outcomes while supporting physicians in the treatment of glaucoma and ocular surface disease.

Its primary products include the OMNI Surgical System, a minimally invasive glaucoma surgery device used to reduce intraocular pressure by improving the eye's natural fluid outflow pathways, and the TearCare System, a thermal pulsation technology designed to treat meibomian gland dysfunction, a common cause of evaporative dry eye disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.